| Bhargav Marthambadi, MD | |
|
5354 Reynolds St Ste 424, Savannah, GA 31405-6011 | |
| (912) 819-5999 | |
| (912) 819-5980 |
| Full Name | Bhargav Marthambadi |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 9 Years |
| Location | 5354 Reynolds St Ste 424, Savannah, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124475595 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Grady Memorial Hospital | Atlanta, GA | Hospital |
| Cartersville Medical Center | Cartersville, GA | Hospital |
| Northside Hospital Cherokee | Canton, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allatoona Physician Services Pc | 7517342579 | 30 |
| Emory Medical Care Foundation Inc | 4981501814 | 801 |
| North Atlanta Professional Services Llc | 0840291944 | 296 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
| Entity Name | Emory Medical Care Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063452381 PECOS PAC ID: 4981501814 Enrollment ID: O20031217000968 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
| Entity Name | North Atlanta Professional Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316959869 PECOS PAC ID: 0840291944 Enrollment ID: O20070116000197 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
| Entity Name | Chatham Hosptialists, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336290667 PECOS PAC ID: 1456456995 Enrollment ID: O20070412000106 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
| Entity Name | Southland Emergency Medical Services Consolidated, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033464391 PECOS PAC ID: 4183871320 Enrollment ID: O20120823000503 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
| Entity Name | Southland Hawkinsville Emergency Medical Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891100962 PECOS PAC ID: 2769600642 Enrollment ID: O20140908000486 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
| Entity Name | Southland Cochran Emergency Medical Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205241395 PECOS PAC ID: 9638398027 Enrollment ID: O20140917001247 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
| Entity Name | Southland Taylor Hospitalist Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093120909 PECOS PAC ID: 6800015959 Enrollment ID: O20140922002775 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
| Entity Name | Southland Consolidated Emergency Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174917124 PECOS PAC ID: 2860792066 Enrollment ID: O20151119001289 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
| Entity Name | Southland Optim Screven Emergency Medical Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174917157 PECOS PAC ID: 9739480021 Enrollment ID: O20151210000476 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
| Entity Name | Southland Optim Jenkins Emergency Medical Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265826242 PECOS PAC ID: 9537461538 Enrollment ID: O20160107002680 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
| Entity Name | Southland Dodge Emergency Medical Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851958607 PECOS PAC ID: 8224360805 Enrollment ID: O20191031001338 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
| Entity Name | Southland Burke Emergency Medical Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235885815 PECOS PAC ID: 9537547401 Enrollment ID: O20220606000360 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
| Entity Name | Allatoona Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497482350 PECOS PAC ID: 7517342579 Enrollment ID: O20220913000203 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bhargav Marthambadi, MD 5354 Reynolds St Ste 424, Savannah, GA 31405-6011 Ph: (912) 819-5999 | Bhargav Marthambadi, MD 5354 Reynolds St Ste 424, Savannah, GA 31405-6011 Ph: (912) 819-5999 |
News Archive
Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine that began on September 13, 2010.
A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.
Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
› Verified 6 days ago
Gina Francois, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5354 Reynolds St Ste 424, Savannah, GA 31405 Phone: 912-819-5999 Fax: 912-819-5980 | |
Ariana Dremonas, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5354 Reynolds St, Suite 424, Savannah, GA 31405 Phone: 912-819-5999 Fax: 912-819-5980 | |
Frank Conrad Duerson Iii, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5354 Reynolds St, Suite 424, Savannah, GA 31405 Phone: 912-819-5999 Fax: 912-819-5980 | |
Dr. Candace L Wilson, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 5354 Reynolds St Ste 424, Savannah, GA 31405 Phone: 912-819-5999 | |
Nadine N Von Taaffe, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 5354 Reynolds St, Ste 424, Savannah, GA 31405 Phone: 912-819-5999 Fax: 912-819-5980 | |
Tooba Anum, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 5354 Reynolds St Ste 424, Savannah, GA 31405 Phone: 912-819-5999 Fax: 912-819-5980 | |
Dr. Anurita Dass, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4700 Waters Ave, Savannah, GA 31404 Phone: 912-350-1316 Fax: 912-350-2156 |